THX Pharma: Annual Results and Cash Flow Statement

THX Pharma, a Lyon-based biopharmaceutical company, announces its 2025 annual results with a strong cash position of €22.3 million as of March 31, 2026. The strategic partnership with Biocodex is central to this success. Biocodex is covering the costs of the Phase 3 clinical trial for Batten-1, allowing THX Pharma to confidently pursue its clinical developments, particularly TX01 and Batten-1.

The licensing agreements provide for rapid commercialization in Europe and beyond from 2027 for TX01. Despite a net loss of €3 million, the increase in upfront payments and subsidies, such as that from Bpifrance, support the company.

Recent developments include a change in governance and a strategic refocusing. These efforts aim to strengthen THX Pharma's position in the rare neurological disease market, capitalizing on clinical advances and financial partnerships.